Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17253974 | BREAST CANCER SPLICE VARIANTS | December 2020 | March 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17122678 | METHODS FOR ANALYZING CELLS | December 2020 | February 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17252571 | NON-INVASIVE DETECTION OF GASTRIC CANCER BY DETECTING THE METHYLATION OF REPRIMO-LIKE IN THE BLOOD | December 2020 | April 2023 | Allow | 28 | 2 | 0 | Yes | No |
| 17058926 | L1TD1 AS PREDICTIVE BIOMARKER OF COLON CANCER | November 2020 | September 2023 | Abandon | 34 | 2 | 1 | No | No |
| 17057410 | TUMOR MARKER, METHYLATION DETECTION REAGENT, KIT AND USE THEREOF | November 2020 | September 2023 | Allow | 34 | 3 | 1 | Yes | No |
| 16950053 | METHOD FOR DIAGNOSING CANCER BY MEANS OF BIOPSY CELL SAMPLE | November 2020 | September 2023 | Abandon | 34 | 2 | 1 | Yes | No |
| 17089491 | PROSTATE CANCER AGGRESSIVENESS BIOMARKERS | November 2020 | January 2023 | Abandon | 27 | 2 | 1 | No | No |
| 17087108 | DIAGNOSTIC METHODS USING HIGH-THROUGHPUT TCR� SEQUENCING AND USES THEREOF | November 2020 | July 2023 | Abandon | 32 | 1 | 1 | No | No |
| 17051781 | METHOD FOR PREPARING RATIOMETRIC ELECTROCHEMICAL miR3123 APTASENSOR BASED ON METAL-ORGANIC FRAMEWORK COMPOSITE | October 2020 | July 2021 | Allow | 8 | 0 | 0 | No | No |
| 17078924 | DETECTION OF LUNG NEOPLASIA BY AMPLIFICATION OF RNA SEQUENCES | October 2020 | June 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 17048791 | METHODS AND KITS FOR DIAGNOSIS AND TRIAGE OF PATIENTS WITH COLORECTAL LIVER METASTASES | October 2020 | April 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17069160 | DETERMINATION OF RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE BY MEASURING URINARY LEVELS OF PODOCIN AND NEPHRIN MESSENGER RNA | October 2020 | July 2023 | Abandon | 33 | 3 | 1 | No | No |
| 17046454 | METHODS FOR MONITORING AND TREATING PROSTATE CANCER | October 2020 | June 2023 | Abandon | 32 | 2 | 1 | Yes | No |
| 17036424 | COMBINATIONS, DETECTION METHODS AND KITS OF DNA METHYLATION BIOMARKER | September 2020 | August 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 17042593 | METHYLATION-BASED BIOMARKERS IN BREAST CANCER SCREENING, DIAGNOSIS, OR PROGNOSIS | September 2020 | August 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 17027221 | DETECTION OF ADVANCED ADENOMA AND/OR EARLY STAGE COLORECTAL CANCER | September 2020 | June 2023 | Abandon | 33 | 2 | 1 | No | No |
| 17022248 | DIAGNOSTIC ASSAY FOR CANCER | September 2020 | October 2022 | Abandon | 25 | 1 | 0 | No | No |
| 17011519 | MOLECULAR SUBTYPING OF SMALL CELL LUNG CANCER TO PREDICT THERAPEUTIC RESPONSES | September 2020 | March 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 16772625 | METHOD FOR AIDING DETECTION OF PANCREATIC CANCER | September 2020 | January 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16970071 | Method for Generating a Profile of the DNA Repair Capabilities of Tumour Cells and the Uses Thereof | September 2020 | February 2023 | Abandon | 30 | 1 | 1 | No | No |
| 16977281 | METHODS FOR PROSTATE CANCER DETECTION | September 2020 | August 2022 | Allow | 23 | 2 | 1 | Yes | No |
| 16948046 | COMPOSITIONS AND METHODS FOR ONCOLOGY PRECISION ASSAYS | August 2020 | May 2022 | Allow | 20 | 2 | 1 | Yes | No |
| 16971163 | METHOD FOR DETERMINING DERMATOPHYTES | August 2020 | February 2023 | Abandon | 30 | 2 | 1 | No | No |
| 16969296 | TUMOR MINIMAL RESIDUAL DISEASE STRATIFICATION | August 2020 | October 2024 | Abandon | 50 | 5 | 1 | No | No |
| 16969168 | METHOD OF IDENTIFYING TUMOR SPECIFIC MACROMOLECULAR ISOFORMS | August 2020 | October 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16989125 | BCR-ABL VARIANTS | August 2020 | October 2021 | Allow | 15 | 1 | 0 | No | No |
| 16965409 | MULTI-COLOR FISH TEST FOR BLADDER CANCER DETECTION | July 2020 | June 2023 | Allow | 35 | 3 | 1 | Yes | No |
| 16935232 | Sidwf1 GENE CONTROLLING INTERNODE LENGTH IN SESAME | July 2020 | October 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16934850 | METHODS AND COMPOSITIONS FOR THE PROGNOSIS AND TREATMENT OF RELAPSED LEUKEMIA | July 2020 | June 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16915254 | PROGNOSIS BIOMARKERS FOR TRIPLE-NEGATIVE BREAST CANCER | June 2020 | February 2022 | Allow | 20 | 1 | 0 | No | No |
| 16957536 | METHOD FOR DIAGNOSING CHOLANGIOCARCINOMA VIA BACTERIAL METAGENOMIC ANALYSIS | June 2020 | August 2023 | Allow | 38 | 4 | 0 | Yes | No |
| 16955989 | METHOD OF SELECTION OF AN IRE1-INHIBITOR THERAPY FOR PATIENT SUFFERING FROM CANCER | June 2020 | August 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 16955732 | METHODS AND DEVICES FOR DETECTING AND QUANTIFYING CELL-FREE DNA FRAGMENTS | June 2020 | April 2024 | Abandon | 46 | 4 | 1 | No | No |
| 16772650 | METHOD FOR ASSISTING IN DETECTION OF BREAST CANCER | June 2020 | May 2022 | Abandon | 23 | 1 | 1 | No | No |
| 16771983 | METHOD FOR ASSISTING DETECTION OF HEAD AND NECK CANCER | June 2020 | May 2022 | Abandon | 23 | 1 | 1 | No | No |
| 16893579 | Lung Microbiome Isolation and Cultivation | June 2020 | June 2023 | Allow | 36 | 3 | 1 | No | No |
| 16889659 | METHODS AND SYSTEMS FOR IMPROVING PATIENT MONITORING AFTER SURGERY | June 2020 | November 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16864518 | METHODS OF PROGNOSIS IN HIGH-GRADE SEROUS OVARIAN CANCER | May 2020 | January 2023 | Allow | 33 | 2 | 1 | Yes | Yes |
| 16760541 | GENETIC REGULATION OF IMMUNORESPONSE BY CHROMOSOME INTERACTIONS | April 2020 | July 2023 | Allow | 38 | 3 | 1 | No | No |
| 16759265 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | April 2020 | May 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16857767 | Biomarkers For Head And Neck Cancer And Methods Of Their Use | April 2020 | April 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16757231 | METHOD FOR DIAGNOSING LYMPHOMA VIA BACTERIAL METAGENOMIC ANALYSIS | April 2020 | March 2023 | Allow | 34 | 3 | 1 | Yes | No |
| 16849067 | NONINVASIVE DIAGNOSTICS BY SEQUENCING 5-HYDROXYMETHYLATED CELL-FREE DNA | April 2020 | May 2022 | Abandon | 25 | 1 | 1 | No | No |
| 16849071 | NONINVASIVE DIAGNOSTICS BY SEQUENCING 5-HYDROXYMETHYLATED CELL-FREE DNA | April 2020 | November 2021 | Abandon | 19 | 1 | 0 | No | No |
| 16848498 | NONINVASIVE DIAGNOSTICS BY SEQUENCING 5-HYDROXYMETHYLATED CELL-FREE DNA | April 2020 | December 2023 | Abandon | 44 | 4 | 0 | No | No |
| 16848515 | NONINVASIVE DIAGNOSTICS BY SEQUENCING 5-HYDROXYMETHYLATED CELL-FREE DNA | April 2020 | September 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16753747 | METHYLATION MARKERS FOR DIAGNOSING CANCER | April 2020 | June 2024 | Abandon | 51 | 4 | 1 | No | No |
| 16652503 | METHOD FOR BODY FLUID IDENTIFICATION | March 2020 | November 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16832449 | METHODS AND SYSTEMS FOR DETECTING TISSUE CONDITIONS | March 2020 | May 2022 | Abandon | 25 | 1 | 1 | No | No |
| 16650916 | METHOD AND KIT FOR PREDICTING THERAPEUTIC EFFECTIVENESS OF CHEMOTHERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS | March 2020 | April 2022 | Abandon | 24 | 1 | 1 | No | No |
| 16828289 | NOVEL GENE CLASSIFIERS AND USES THEREOF IN SKIN CANCERS | March 2020 | August 2022 | Allow | 29 | 2 | 1 | Yes | No |
| 16826390 | CTNNB1 MUTATION DETECTION KIT, METHOD, AND USE IN HCC DETECTION AND MANAGEMENT | March 2020 | July 2022 | Abandon | 28 | 2 | 1 | No | No |
| 16819070 | METHODS FOR PREDICTING PROSTATE CANCER AND USES THEREOF | March 2020 | January 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 16646734 | HMGB1 RNA And Methods Therefor | March 2020 | October 2023 | Abandon | 43 | 0 | 1 | No | No |
| 16814321 | METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT | March 2020 | October 2021 | Allow | 19 | 2 | 0 | No | No |
| 16814085 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | March 2020 | March 2022 | Allow | 24 | 2 | 1 | No | No |
| 16645250 | NON-INVASIVE METHOD FOR THE EARLY DIAGNOSIS OF GASTRIC CANCER USING AS A BIOMARKER THE METHYLATION LEVELS IN THE DNA SEQUENCE OF MICRORNA-335-5P PROMOTER | March 2020 | July 2022 | Allow | 28 | 2 | 0 | Yes | No |
| 16807527 | Method for detecting polynucleotide using FRET-PAINT | March 2020 | December 2023 | Abandon | 46 | 4 | 1 | No | No |
| 16805637 | SYSTEMS, COMPOSITIONS, AND METHODS FOR TARGET ENTITY DETECTION | February 2020 | June 2021 | Allow | 16 | 2 | 0 | No | No |
| 16639065 | PROGNOSTIC MARKERS FOR CANCER RECURRENCE | February 2020 | March 2022 | Abandon | 25 | 1 | 1 | No | No |
| 16790510 | METHOD OF MEASURING CHIMERISM | February 2020 | January 2022 | Abandon | 23 | 1 | 1 | No | No |
| 16637552 | METHOD AND SYSTEM FOR ANALYSIS OF DNA METHYLATION AND USE OF SAME TO DETECT CANCER | February 2020 | September 2023 | Abandon | 44 | 4 | 0 | Yes | No |
| 16748691 | OLIGONUCLEOTIDE-COMPRISING CELLULAR COMPONENT-BINDING REAGENTS AND METHODS OF USING THE SAME | January 2020 | July 2023 | Allow | 42 | 4 | 1 | No | No |
| 16746721 | Markers of Triple-Negative Breast Cancer and Uses Thereof | January 2020 | November 2022 | Abandon | 34 | 2 | 1 | Yes | Yes |
| 16631902 | METHOD FOR MOLECULAR TYPING OF TUMORS IN A SINGLE TARGETED NEXT GENERATION SEQUENCING EXPERIMENT | January 2020 | February 2022 | Abandon | 25 | 1 | 1 | No | No |
| 16632006 | METHODS FOR DETERMINING RESPONSE TO PARP INHIBITORS | January 2020 | April 2023 | Allow | 39 | 2 | 1 | No | No |
| 16739820 | CO-ASSAYS TO FUNCTIONAL CANCER BIOMARKER ASSAYS | January 2020 | November 2023 | Abandon | 46 | 2 | 1 | No | No |
| 16630021 | N-CADHERIN AND FGFR1 AND/OR FGFR4 FOR USE IN PREDICTING THE RESPONSE OF PATIENTS TO A LUNG CANCER TREATMENT AND METHOD AND KIT BASED ON SAID USE | January 2020 | May 2022 | Allow | 28 | 2 | 1 | Yes | No |
| 16727064 | DEVICES AND METHODS FOR MOLECULE DETECTION BASED ON THERMAL STABILITIES OF MAGNETIC NANOPARTICLES | December 2019 | December 2022 | Allow | 35 | 2 | 0 | Yes | No |
| 16626781 | KIT, DEVICE, AND METHOD FOR DETECTING LUNG CANCER | December 2019 | December 2022 | Allow | 36 | 3 | 1 | Yes | No |
| 16592867 | PERSONALIZED THERAPEUTIC APPROACHES TO PROSTATE CANCER | December 2019 | February 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16622419 | METHOD FOR DETERMINING THE SUSCEPTIBILITY OF A PATIENT SUFFERING FROM PROLIFERATIVE DISEASE TO TREATMENT USING AN AGENT WHICH TARGETS A COMPONENT OF THE PD I/PD-LI PATHWAY | December 2019 | November 2022 | Abandon | 36 | 1 | 1 | No | No |
| 16614507 | COMPOSITE EPIGENETIC BIOMARKERS FOR ACCURATE SCREENING, DIAGNOSIS AND PROGNOSIS OF COLORECTAL CANCER | November 2019 | August 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16683897 | DETECTION METHOD FOR NEISSERIA GONORRHOEAE | November 2019 | October 2021 | Allow | 23 | 1 | 1 | Yes | No |
| 16681046 | METHOD FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILES IN PERIPHERAL BLOOD MONONUCLEAR CELLS | November 2019 | November 2021 | Abandon | 25 | 0 | 1 | No | No |
| 16680460 | DETECTION OF MYCOPLASMA IN CELL CULTURES AND CELL CULTURE DERIVED BIOLOGICALS | November 2019 | October 2022 | Abandon | 35 | 2 | 1 | No | No |
| 16462655 | METHOD FOR PREDICTING PROGNOSIS OF BREAST CANCER PATIENT | November 2019 | July 2023 | Allow | 50 | 2 | 1 | Yes | No |
| 16666449 | METHOD FOR DETERMINING CROSS CONTAMINATION OF MOUSE GENES FOR HUMAN CELLS IN A PATIENT-DERIVED XENOGRAFT CELLS | October 2019 | May 2021 | Allow | 19 | 1 | 0 | No | No |
| 16662352 | WHOLE-GENOME HAPLOTYPE RECONSTRUCTION | October 2019 | June 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16603451 | Detection Reagent, Detection Kit and Detection Method for ITGA4 Gene Methylation | October 2019 | May 2023 | Allow | 43 | 3 | 1 | Yes | No |
| 16499849 | METHOD OF DETECTING A FETAL CHROMOSOMAL ABNORMALITY | September 2019 | June 2023 | Abandon | 45 | 2 | 1 | No | No |
| 16575940 | PROGNOSTIC METHOD FOR INDIVIDUALS WITH PROSTATE CANCER | September 2019 | April 2024 | Abandon | 55 | 4 | 2 | No | No |
| 16567233 | PROGNOSTIC METHODS AND SYSTEMS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA | September 2019 | March 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16491559 | HYPOXIC NK CELLS AND METHODS THEREFOR | September 2019 | October 2021 | Allow | 26 | 3 | 1 | Yes | No |
| 16555819 | BIOMARKERS FOR EARLY DIAGNOSIS AND DIFFERENTIATION OF MYCOBACTERIAL INFECTION | August 2019 | August 2023 | Allow | 48 | 5 | 1 | No | No |
| 16542782 | ASSAYS FOR FUNGAL INFECTION | August 2019 | August 2021 | Allow | 24 | 1 | 1 | Yes | No |
| 16541622 | V1B RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF PATIENTS HAVING AN ELEVATED AVP LEVEL AND/OR AN ELEVATED COPEPTIN LEVEL | August 2019 | August 2020 | Allow | 12 | 2 | 1 | Yes | No |
| 16335553 | COMPOSITIONS AND METHODS FOR ASSESSING IMMUNE RESPONSE | August 2019 | April 2022 | Allow | 37 | 2 | 1 | Yes | No |
| 16484546 | Target Gene Identifying Method for Tumor Treatment | August 2019 | September 2023 | Abandon | 49 | 4 | 1 | No | No |
| 16475054 | EARLY DIAGNOSIS METHOD AND KIT FOR BREAST CANCER | June 2019 | October 2023 | Abandon | 52 | 3 | 1 | No | No |
| 16421793 | CIRCULATING miRNAs AS MARKERS FOR BREAST CANCER | May 2019 | March 2023 | Abandon | 46 | 3 | 1 | No | No |
| 16422377 | DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL COSTIMULATION AND USES THEREOF | May 2019 | March 2020 | Abandon | 9 | 0 | 1 | No | No |
| 16461025 | RISK SCORES BASED ON HUMAN PHOSPHODIESTERASE 4 D VARIANT 7 EXPRESSION | May 2019 | May 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16349976 | METHODS AND DEVICES FOR DETECTING HEPATITIS C VIRUS | May 2019 | August 2024 | Abandon | 60 | 7 | 1 | Yes | No |
| 16412057 | COMPOSITIONS AND METHODS FOR PROGNOSING AND TREATING COLORECTAL CANCER | May 2019 | May 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16397825 | METHODS FOR TREATMENT AND DIAGNOSIS OF ENDOMETRIOSIS | April 2019 | April 2023 | Allow | 48 | 3 | 1 | Yes | No |
| 16341907 | INDOLEAMINE-2,3-DIOXYGENASE ASSAY FOR PROSTATE CANCER DIAGNOSIS AND PROGNOSIS | April 2019 | June 2021 | Abandon | 26 | 1 | 1 | Yes | No |
| 16361333 | NANOPLASMONIC BIOSENSOR AND METHOD FOR DETECTING DISEASE MARKERS USING THE SAME | March 2019 | November 2022 | Allow | 44 | 4 | 1 | Yes | No |
| 16330444 | METHOD FOR DETECTING ABERRANT DNA METHYLATION OF THE TERT PROMOTER | March 2019 | April 2023 | Abandon | 49 | 4 | 1 | No | No |
| 16322831 | METHOD FOR PROGNOSING AND DIAGNOSING TUMORS | February 2019 | August 2024 | Abandon | 60 | 5 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SALMON, KATHERINE D.
With a 15.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 7.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SALMON, KATHERINE D works in Art Unit 1634 and has examined 731 patent applications in our dataset. With an allowance rate of 27.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner SALMON, KATHERINE D's allowance rate of 27.9% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SALMON, KATHERINE D receive 2.66 office actions before reaching final disposition. This places the examiner in the 74% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SALMON, KATHERINE D is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +43.4% benefit to allowance rate for applications examined by SALMON, KATHERINE D. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 12.1% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 19.0% of cases where such amendments are filed. This entry rate is in the 24% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 58.1% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 72.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 84.4% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.8% of allowed cases (in the 64% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.